Posted by Michael Wonder on 18 Jul 2022
AbbVie submits marketing authorisation application to EMA for atogepant for the preventive treatment of migraine
18 July 2022 - The submission is based on two pivotal Phase 3 studies evaluating atogepant in adult patients with episodic and chronic migraine.
AbbVie today announced it has submitted a marketing authorisation application to the EMA for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.
